Skip to main content

Table 2 Univariate and multivariate analyses of OS and BCSS for the MBC variables included in the study before PSM

From: The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database

Characteristics

Univariate

Multivariate

OS

BCSS

OS

BCSS

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Age at diagnosis (< 60 as ref.)

 ≥ 60

1.92 (1.63–2.26)

< 0.01

1.23 (1.02–1.48)

< 0.05

1.81 (1.51–2.16)

< 0.01

1.36 (1.11–1.66)

< 0.001

Race (white as ref.)

 Black

1.02 (0.82–1.27)

0.843

1.12 (0.88–1.43)

0.364

1.01 (0.81–1.26)

0.958

0.97 (0.76–1.25)

0.828

 Others

0.91 (0.65–1.26)

0.583

0.98 (0.68–1.42)

0.922

0.95 (0.69–1.32)

0.763

0.97 (0.67–1.41)

0.872

Marital status (single as ref.)

 Married

0.92 (0.74–1.14)

0.449

0.78 (0.62–1.00)

< 0.05

0.93 (0.74–1.17)

0.54

0.92 (0.71–1.18)

0.506

Grade (G1 as ref.)

 G2

1.23 (0.79–1.93)

0.36

1.08 (0.61–1.92)

0.786

1.08 (0.69–1.69)

0.747

0.93 (0.52–1.65)

0.801

 G3

1.5 (1.01–2.25)

< 0.05

1.77 (1.07–2.92)

< 0.05

1.18 (0.78–1.77)

0.438

1.14 (0.69–1.9)

0.605

 G4

1.94 (1.20–3.15)

< 0.01

2.50 (1.40–4.49)

< 0.01

1.56 (0.96–2.54)

0.076

1.65 (0.92–2.98)

0.095

ER status (negative as ref.)

 Positive

0.9 (0.73–1.12)

0.36

0.88 (0.68–1.13)

0.318

0.88 (0.68–1.14)

0.316

0.8 (0.59–1.08)

0.146

PR status (negative as ref.)

 Positive

0.8 (0.62–1.03)

0.077

0.87 (0.66–1.16)

0.339

0.81 (0.60–1.09)

0.162

0.95 (0.68–1.34)

0.779

Stage T (≤ 5 cm as ref.)

 > 5 cm

3.65 (3.11–4.28)

< 0.01

4.55 (3.79–5.46)

<  0.001

2.92 (2.44–3.49)

< 0.01

3.44 (2.79–4.24)

< 0.001

Stage N (N0 as ref.)

 N1

1.79 (1.48–2.17)

< 0.01

2.35 (1.89–2.91)

<  0.001

1.55 (1.26–1.91)

< 0.01

1.78 (1.41–2.25)

< 0.001

 N2

3.45 (2.60–4.59)

< 0.01

4.01 (2.91–5.52)

<  0.001

2.55 (1.88–3.46)

< 0.01

2.49 (1.76–3.51)

< 0.001

 N3

3.86 (2.78–5.36)

< 0.01

5.03 (3.54–7.17)

<  0.001

2.91 (2.06–4.11)

< 0.01

3.33 (2.29–4.84)

< 0.001

Breast operation (lumpectomy as ref.)

 Mastectomy

2.56 (2.14–3.06)

< 0.01

2.75 (2.22–3.41)

<  0.001

1.3 (1.05–1.61)

< 0.05

1.32 (1.02–1.70)

< 0.05

Chemotherapy (not done/unknown as ref.)

 Done

0.62 (0.53–0.72)

< 0.01

0.99 (0.82–1.2)

0.934

0.71 (0.60–0.85)

< 0.001

1.02 (0.82–1.27)

0.848

Radiotherapy (not done as ref.)

 Done

0.62 (0.53–0.73)

< 0.001

0.73 (0.61–0.88)

< 0.001

0.73 (0.61–0.88)

0.001

0.71 (0.58–0.88)

< 0.01

Axilla LN operation (SLNB as ref.)

 ALND

1.91 (1.62–2.25)

< 0.001

2.18 (1.79–2.65)

< 0.001

1.17 (0.97–1.42)

0.096

1.14 (0.91–1.43)

0.254

  1. SLNB Sentinel lymph node biopsy, ALND axillary lymph node dissection
  2. Significant results are in italic
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us